To date, 23 patients with advanced/metastatic solid tumors have been enrolled (3+3 protocol).

  • Toxicity: MTD has not been reached. Treatment was well-tolerated with no cumulative toxicity.
  • Pharmacokinetic analysis: AUC, Cmax and t½ were calculated and were dose-dependent and approximately linear.
  • Efficacy: 5 of 15 evaluable patients have been treated for at least 3 cycles and were considered SD through this period.